These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33915224)

  • 1. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
    Zhou M; Luo C; Zhou Z; Li L; Huang Y
    J Control Release; 2021 Jun; 334():248-262. PubMed ID: 33915224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
    Wang Z; Cordova LE; Chalasani P; Lu J
    Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.
    Yokoi T; Oba T; Kajihara R; Abrams SI; Ito F
    Sci Rep; 2021 Nov; 11(1):21992. PubMed ID: 34754037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer.
    Wang Y; Chen Y; Ji DK; Huang Y; Huang W; Dong X; Yao D; Wang D
    J Nanobiotechnology; 2024 Aug; 22(1):461. PubMed ID: 39090622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference.
    Deng ZW; Yang JK; Qiu KJ; Zhang TJ; He Z; Wang N; Chen XG; Liu Y
    J Control Release; 2024 Jun; 370():453-467. PubMed ID: 38697315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.
    Haq ATA; Yang PP; Jin C; Shih JH; Chen LM; Tseng HY; Chen YA; Weng YS; Wang LH; Snyder MP; Hsu HL
    Theranostics; 2024; 14(5):2167-2189. PubMed ID: 38505617
    [No Abstract]   [Full Text] [Related]  

  • 9. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
    Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
    Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
    Yang Z; Sun JK; Lee MM; Chan MK
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
    Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
    Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy.
    Li Z; Wang Y; Shen Y; Qian C; Oupicky D; Sun M
    Sci Adv; 2020 May; 6(20):eaaz9240. PubMed ID: 32440550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
    Luo X; Wang H; Ji D
    Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.